Last 7 days
-1.3%
Last 30 days
-9.2%
Last 90 days
-13.2%
Trailing 12 Months
-24.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-31 | Denton David M | sold (taxes) | -616,798 | 38.02 | -16,223 | chief financial officer & evp |
2023-05-08 | Gottlieb Scott | bought | 38,580 | 38.58 | 1,000 | - |
2023-05-05 | Gottlieb Scott | bought | 38,425 | 38.425 | 1,000 | - |
2023-03-31 | Pao William | sold (taxes) | -901,476 | 40.8 | -22,095 | executive vice president |
2023-03-15 | DAMICO JENNIFER B. | sold | -396,678 | 40.02 | -9,912 | svp & controller |
2023-02-27 | SAHNI PAYAL | sold (taxes) | -52,891 | 40.78 | -1,297 | executive vice president |
2023-02-27 | McDermott Michael | sold (taxes) | -125,643 | 40.78 | -3,081 | executive vice president |
2023-02-27 | DAMICO JENNIFER B. | sold (taxes) | -58,193 | 40.78 | -1,427 | svp & controller |
2023-02-25 | SAHNI PAYAL | acquired | 204,202 | 22.89 | 8,921 | executive vice president |
2023-02-25 | LANKLER DOUGLAS M | sold (taxes) | -1,101,740 | 41.75 | -26,389 | executive vice president |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -7.91 | -995,067 | 4,785,640 | 2.00% |
2023-09-18 | CAPE ANN SAVINGS BANK | added | 4.7 | -40,824 | 654,775 | 0.44% |
2023-09-15 | CJM Wealth Advisers, Ltd. | sold off | -100 | -284,577 | - | -% |
2023-09-14 | IMS Capital Management | added | 22.05 | 264,254 | 2,980,970 | 1.66% |
2023-09-13 | CGC Financial Services, LLC | new | - | 72,746 | 72,746 | 0.05% |
2023-09-12 | DCM Advisors, LLC | reduced | -0.06 | -251,082 | 2,221,190 | 0.95% |
2023-09-12 | Prosperity Financial Group, Inc. | added | 29.56 | 45,755 | 323,481 | 0.28% |
2023-09-12 | Prosperity Wealth Management, Inc. | added | 1.93 | -23,380 | 256,100 | 0.17% |
2023-09-12 | Farther Finance Advisors, LLC | added | 14.97 | 21,065 | 648,487 | 0.14% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | added | 180 | 267,467 | 442,877 | 0.13% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.94% | 501,636,220 | SC 13G/A | |
Feb 07, 2023 | state street corp | 5.08% | 284,943,697 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.9% | 442,868,761 | SC 13G/A | |
Feb 14, 2022 | state street corp | 5.09% | 285,771,591 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.29% | 465,274,925 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.3% | 409,985,645 | SC 13G/A | |
Feb 12, 2021 | state street corp | 5.03% | 279,831,373 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 8.06% | 447,958,747 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.1% | 396,973,512 | SC 13G/A | |
Feb 13, 2020 | state street corp | 5.28% | 292,628,794 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 18, 2023 | 4 | Insider Trading | |
Sep 18, 2023 | 4 | Insider Trading | |
Sep 18, 2023 | 4 | Insider Trading | |
Sep 13, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 11, 2023 | SC 13D/A | 13D - Major Acquisition | |
Sep 01, 2023 | 4 | Insider Trading | |
Sep 01, 2023 | 4 | Insider Trading | |
Sep 01, 2023 | 4 | Insider Trading | |
Aug 16, 2023 | 4 | Insider Trading | |
Aug 16, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
MID-CAP | ||||||||
RETA | 6.5B | - | 1.75% | 544.26% | -74.04 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -11.88% | -19.94% | 34.62 | 2.37 | 0.62% | -24.59% |
INVA | 832.3M | 244.3M | -4.13% | 4.68% | 4.22 | 3.41 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
ACRS | 479.1M | 31.2M | -7.77% | -52.62% | -4.55 | 15.37 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -13.04% | -44.44% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
4.9%
3.1%
-2.3%
-0.2%
56.1%
11.5%
0%
Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -16.1% | 77,944 | 92,952 | 100,330 | 99,879 | 101,276 | 92,433 | 81,288 | 68,877 | 55,119 | 46,084 | 41,651 | 32,067 | 34,470 | 37,870 | 40,905 | 40,217 | 40,835 | 41,037 | 40,825 | 53,373 | 53,243 |
S&GA Expenses | 3.1% | 14,951 | 14,502 | 13,677 | 13,136 | 12,644 | 12,519 | 12,703 | 12,338 | 12,097 | 11,833 | 11,597 | 10,474 | 11,076 | 11,928 | 12,726 | 12,274 | 12,508 | 12,539 | 12,612 | 15,003 | 15,013 |
EBITDA | -100.0% | - | 33,357 | 36,171 | 34,708 | 33,956 | 34,344 | 30,969 | - | - | 18,239 | 13,819 | 8,775 | 17,376 | 18,477 | 18,827 | 25,371 | 18,628 | - | - | - | - |
EBITDA Margin | -100.0% | - | 0.36* | 0.36* | 0.35* | 0.34* | 0.37* | 0.38* | - | - | 0.45* | 0.33* | 0.20* | 0.37* | 0.36* | 0.36* | 0.48* | 0.35* | - | - | - | - |
Interest Expenses | 6.0% | 1,492 | 1,408 | 1,442 | 1,383 | 1,440 | 1,475 | 1,467 | 1,549 | 1,529 | 1,614 | 1,641 | 1,638 | 1,688 | 1,674 | 1,587 | 1,589 | 1,396 | 1,437 | 1,311 | 1,385 | 1,361 |
Earnings Before Taxes | -28.7% | 22,771 | 31,949 | 34,729 | 33,325 | 32,167 | 27,669 | 24,311 | 21,082 | 13,809 | 9,886 | 7,036 | -1,431 | 8,726 | 9,841 | 11,321 | 9,954 | 3,404 | 3,790 | 3,594 | 13,785 | 13,193 |
EBT Margin | -100.0% | - | 0.34* | 0.35* | 0.33* | 0.32* | 0.30* | 0.30* | 0.30* | 0.24* | 0.30* | 0.18* | 0.03* | 0.21* | 0.22* | 0.22* | - | - | - | - | - | - |
Net Income | -26.1% | 21,472 | 29,051 | 31,372 | 29,771 | 29,309 | 24,966 | 21,979 | 19,432 | 12,755 | 10,681 | 9,159 | 7,730 | 13,941 | 15,498 | 16,026 | 16,217 | 12,651 | 11,477 | 11,153 | 23,821 | 22,547 |
Net Income Margin | -100.0% | - | 0.31* | 0.31* | 0.30* | 0.29* | 0.27* | 0.27* | 0.28* | 0.23* | 0.26* | 0.22* | 0.18* | 0.30* | 0.31* | 0.31* | - | - | - | - | - | - |
Free Cashflow | -100.0% | - | 20,206 | 26,031 | 23,362 | 28,443 | 31,783 | 29,869 | 29,814 | 21,141 | 13,451 | 12,151 | 10,566 | 12,892 | 11,962 | 10,516 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 12.6% | 220,168 | 195,617 | 197,000 | 195,350 | 195,290 | 183,841 | 181,000 | 179,188 | 169,920 | 158,818 | 154,000 | 178,983 | 178,000 | 166,336 | 167,594 | 170,446 | 156,199 | 155,421 | 159,000 | 168,000 | 164,980 |
Current Assets | 46.5% | 73,347 | 50,078 | 51,259 | 70,403 | 67,466 | 54,420 | 59,693 | 57,900 | 48,814 | 39,533 | 35,067 | 47,739 | 46,424 | 34,738 | 32,803 | 33,459 | 47,073 | 45,290 | 49,926 | 41,583 | 37,303 |
Cash Equivalents | 21.5% | 2,632 | 2,166 | 416 | 1,298 | 1,824 | 2,513 | 1,983 | 2,034 | 2,418 | 1,809 | 1,825 | 1,627 | 1,845 | 2,196 | 1,350 | 2,846 | 1,837 | 2,018 | 1,225 | 3,658 | 2,811 |
Inventory | 8.1% | 10,310 | 9,541 | 8,981 | 9,513 | 10,454 | 9,979 | 9,059 | 8,640 | 8,948 | 8,493 | 8,020 | 9,295 | 8,564 | 8,423 | 7,068 | 8,222 | 8,233 | 8,029 | 7,508 | 8,184 | 8,074 |
Net PPE | 2.6% | 17,488 | 17,052 | 16,274 | 15,441 | 15,244 | 15,109 | 14,882 | 14,436 | 14,224 | 14,011 | 13,745 | 14,403 | 14,113 | 14,040 | 12,969 | 13,701 | 13,521 | 13,467 | 13,385 | 14,036 | 13,919 |
Goodwill | 0.2% | 51,572 | 51,476 | 51,375 | 795 | 49,891 | 50,211 | 49,208 | 49,489 | 49,867 | 49,791 | 49,556 | 59,902 | 58,449 | 58,502 | 48,181 | 58,665 | 53,352 | 53,487 | 42,927 | 55,614 | 55,836 |
Liabilities | 28.1% | 120,875 | 94,381 | 101,288 | 102,459 | 107,821 | 101,155 | 104,013 | 103,221 | 99,605 | 89,953 | 90,756 | 113,487 | 113,370 | 100,998 | 104,148 | 105,051 | 96,274 | 96,263 | 95,664 | 96,174 | 94,856 |
Current Liabilities | -5.2% | 34,647 | 36,562 | 42,138 | 44,314 | 47,410 | 39,268 | 42,671 | 41,803 | 35,664 | 26,652 | 25,920 | 34,154 | 32,723 | 33,890 | 37,304 | 36,974 | 32,030 | 29,423 | 31,858 | 29,013 | 32,156 |
LT Debt, Current | -0.1% | 3,565 | 3,567 | 2,560 | 2,566 | 1,276 | 260 | 1,636 | 2,663 | 3,687 | 3,676 | 2,002 | 2,149 | 1,481 | 337 | 1,462 | 2,431 | 2,139 | 4,471 | 4,776 | 4,255 | 4,262 |
LT Debt, Non Current | 93.5% | 61,356 | 31,704 | 32,884 | 32,629 | 34,294 | 35,656 | 36,000 | 36,250 | 35,354 | 35,347 | 37,133 | 49,785 | 50,529 | 36,281 | 35,955 | 36,044 | 36,168 | 35,733 | 32,909 | 33,652 | 28,935 |
Shareholder's Equity | -2.2% | 99,019 | 101,236 | 95,661 | 92,631 | 87,469 | 82,685 | 77,462 | 75,967 | 70,315 | 68,865 | 63,473 | 65,503 | 64,570 | 65,341 | 63,447 | 65,396 | 59,924 | 59,158 | 63,758 | 71,664 | 70,124 |
Retained Earnings | -1.8% | 128,796 | 131,102 | 125,656 | 122,967 | 116,608 | 111,193 | 103,394 | 102,252 | 96,346 | 95,158 | 90,392 | 100,284 | 100,203 | 101,000 | 97,670 | 100,113 | 94,440 | 93,388 | 89,574 | 91,995 | 89,860 |
Additional Paid-In Capital | 0.2% | 92,329 | 92,153 | 91,802 | 91,359 | 91,183 | 90,844 | 90,591 | 89,973 | 89,336 | 89,002 | 88,674 | 88,161 | 87,886 | 87,680 | 87,428 | 87,099 | 86,963 | 86,635 | 86,253 | 85,828 | 84,898 |
Accumulated Depreciation | 0.3% | 15,554 | 15,514 | 15,174 | 14,931 | 14,969 | 15,358 | 15,074 | 15,403 | 15,328 | 15,105 | 14,812 | 16,636 | 16,889 | 16,929 | 16,789 | 16,728 | 16,389 | 16,158 | 16,591 | 17,078 | 16,844 |
Shares Outstanding | 0.2% | 5,646 | 5,634 | - | 5,607 | 5,593 | 5,617 | - | 5,609 | 5,598 | 5,584 | - | 5,557 | 5,554 | 5,545 | - | 5,545 | 5,562 | 5,635 | - | 5,875 | 5,866 |
Minority Interest | 3.0% | 274 | 266 | 256 | 259 | 261 | 261 | 262 | 275 | 273 | 245 | 235 | 236 | 228 | 312 | 303 | 293 | 357 | 352 | 351 | 346 | 346 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -39.2% | 14,560 | 23,938 | 29,267 | 26,599 | 31,454 | 34,583 | 32,580 | 32,291 | 23,552 | 15,808 | 14,403 | 12,547 | 14,967 | 14,023 | 12,588 | 13,557 | 14,306 | 15,542 | 15,827 | 18,178 | 17,808 |
Share Based Compensation | -15.6% | 752 | 891 | 872 | 1,004 | 1,162 | 1,096 | 1,182 | 973 | 904 | 870 | 755 | 707 | 547 | 559 | 687 | 689 | 928 | 926 | 923 | 927 | 831 |
Cashflow From Investing | -108.7% | -27,207 | -13,035 | -15,783 | -13,959 | -23,408 | -20,232 | -22,546 | -11,630 | -1,073 | -5,947 | -4,271 | -15,434 | -22,675 | -11,566 | -3,945 | -1,876 | 1,980 | 2,408 | 4,525 | 530 | 423 |
Cashflow From Financing | 223.6% | 13,627 | -11,027 | -14,834 | -13,170 | -8,510 | -13,587 | -9,816 | -20,252 | -21,972 | -10,256 | -9,649 | 1,698 | 7,792 | -2,218 | -8,485 | -12,452 | -17,131 | -18,188 | -20,441 | -17,777 | -18,082 |
Buy Backs | - | - | - | 2,000 | 2,000 | 2,000 | 2,000 | - | - | - | - | - | - | - | - | 8,865 | 13,895 | 15,000 | 15,000 | 12,198 | 7,168 | 6,063 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
Jul. 02, 2023 | Jul. 03, 2022 | Jul. 02, 2023 | Jul. 03, 2022 | |||||
Income Statement [Abstract] | ||||||||
Revenues | $ 12,734 | $ 27,742 | $ 31,015 | $ 53,402 | ||||
Costs and expenses: | ||||||||
Cost of sales | [1] | 3,237 | 8,648 | 8,122 | 18,632 | |||
Selling, informational and administrative expenses | [1] | 3,497 | 3,048 | 6,914 | 5,642 | |||
Research and development expenses | [1] | 2,648 | 2,815 | 5,153 | 5,116 | |||
Acquired in-process research and development expenses | 33 | 1 | 55 | 356 | ||||
Amortization of intangible assets | 1,184 | 822 | 2,287 | 1,657 | ||||
Restructuring charges and certain acquisition-related costs | 214 | 189 | 222 | 381 | ||||
Other (income)/deductions––net | (347) | 772 | (277) | 1,122 | ||||
Income from continuing operations before provision/(benefit) for taxes on income | [2] | 2,269 | 11,447 | 8,539 | 20,497 | |||
Provision/(benefit) for taxes on income | (71) | 1,570 | 644 | 2,742 | ||||
Income from continuing operations | 2,340 | 9,877 | 7,895 | 17,756 | ||||
Discontinued operations––net of tax | (2) | 34 | (1) | 26 | ||||
Net income before allocation to noncontrolling interests | 2,338 | 9,911 | 7,894 | 17,781 | ||||
Less: Net income attributable to noncontrolling interests | 11 | 6 | 24 | 12 | ||||
Net income attributable to Pfizer Inc. common shareholders | $ 2,327 | $ 9,906 | $ 7,870 | $ 17,769 | ||||
Earnings per common share––basic: | ||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 0.41 | $ 1.76 | $ 1.40 | $ 3.17 | ||||
Discontinued operations––net of tax (in dollars per share) | 0 | 0.01 | 0 | 0 | ||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 0.41 | 1.77 | 1.40 | 3.17 | ||||
Earnings per common share––diluted: | ||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 0.41 | 1.73 | 1.38 | 3.09 | ||||
Discontinued operations––net of tax (in dollars per share) | 0 | 0.01 | 0 | 0 | ||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 0.41 | $ 1.73 | $ 1.38 | $ 3.10 | ||||
Weighted-average shares––basic | 5,646 | 5,593 | 5,640 | 5,605 | ||||
Weighted-average shares––diluted | 5,713 | 5,712 | 5,720 | 5,735 | ||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Jul. 02, 2023 | Dec. 31, 2022 | ||||
---|---|---|---|---|---|---|
Assets | ||||||
Cash and cash equivalents | $ 2,632 | $ 416 | ||||
Short-term investments | 42,153 | 22,316 | ||||
Trade accounts receivable, less allowance for doubtful accounts: 2023—$471; 2022—$449 | 10,231 | 10,952 | ||||
Inventories | [1] | 10,310 | 8,981 | |||
Current tax assets | 3,194 | 3,577 | ||||
Other current assets | 4,828 | 5,017 | ||||
Total current assets | 73,347 | 51,259 | ||||
Equity-method investments | 11,422 | 11,033 | ||||
Long-term investments | 3,644 | 4,036 | ||||
Property, plant and equipment, less accumulated depreciation: 2023—$15,554; 2022—$15,174 | 17,488 | 16,274 | ||||
Identifiable intangible assets | [2] | 41,406 | 43,370 | |||
Goodwill | 51,572 | 51,375 | ||||
Noncurrent deferred tax assets and other noncurrent tax assets | 8,261 | 6,693 | ||||
Other noncurrent assets | 13,028 | 13,163 | ||||
Total assets | 220,168 | 197,205 | ||||
Liabilities and Equity | ||||||
Short-term borrowings, including current portion of long-term debt: 2023—$3,565; 2022—$2,560 | 3,985 | 2,945 | ||||
Trade accounts payable | 6,081 | 6,809 | ||||
Dividends payable | 2,315 | 2,303 | ||||
Income taxes payable | 2,928 | 1,587 | ||||
Accrued compensation and related items | 1,972 | 3,407 | ||||
Deferred revenues | 1,286 | 2,520 | ||||
Other current liabilities | 16,079 | 22,568 | ||||
Total current liabilities | 34,647 | 42,138 | ||||
Long-term debt | 61,356 | 32,884 | ||||
Pension and postretirement benefit obligations | 2,184 | 2,250 | ||||
Noncurrent deferred tax liabilities | 1,232 | 1,023 | ||||
Other taxes payable | 8,052 | 9,812 | ||||
Other noncurrent liabilities | 13,403 | 13,180 | ||||
Total liabilities | 120,875 | 101,288 | ||||
Commitments and Contingencies | ||||||
Common stock | 478 | 476 | ||||
Additional paid-in capital | 92,329 | 91,802 | ||||
Treasury stock | (114,482) | (113,969) | ||||
Retained earnings | 128,796 | 125,656 | ||||
Accumulated other comprehensive loss | (8,102) | (8,304) | ||||
Total Pfizer Inc. shareholders’ equity | 99,019 | 95,661 | ||||
Equity attributable to noncontrolling interests | 274 | 256 | ||||
Total equity | 99,293 | 95,916 | ||||
Total liabilities and equity | $ 220,168 | $ 197,205 | ||||
|